SIOUX FALLS, S.D.--(BUSINESS WIRE)-- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully ...
Positive clinical results confirm that SAB’s fully-human polyclonal antibodies can be broadly neutralizing to both known and unknown viral variants—a valuable feature when addressing rapidly mutating ...
SEC Staff Accounting Bulletin (SAB) 121 is no more. Today, SAB 122 rescinded the guidance of SAB 121 – the bulletin that “expressed the views of the staff regarding the accounting for obligations to ...
SAB Biotherapeutics vowed to plow on through the fields with a cow-plasma-based COVID-19 treatment after the National Institutes of Health (NIH) dropped out last year. Now, the data harvest from that ...
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, ...
In September 2019, a tiny company named SAB Biotherapeutics signed a little contract with the U.S. Department of Defense (DOD) that included the test development of an antibody treatment into phase 1 ...
MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (SABS) (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 ...
SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression ...
SAB-185 advanced from Phase 2 to the Phase 3 portion of the ACTIV-2 trial based on meeting pre-defined graduation criteria. The interim analysis demonstrated that both the lower and higher doses of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results